1. Home
  2. WK vs AKRO Comparison

WK vs AKRO Comparison

Compare WK & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Workiva Inc.

WK

Workiva Inc.

HOLD

Current Price

$92.05

Market Cap

5.1B

Sector

Technology

ML Signal

HOLD

Logo Akero Therapeutics Inc.

AKRO

Akero Therapeutics Inc.

HOLD

Current Price

$54.54

Market Cap

4.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WK
AKRO
Founded
2008
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.1B
4.5B
IPO Year
2014
2019

Fundamental Metrics

Financial Performance
Metric
WK
AKRO
Price
$92.05
$54.54
Analyst Decision
Strong Buy
Buy
Analyst Count
10
10
Target Price
$104.50
$73.56
AVG Volume (30 Days)
628.7K
1.7M
Earning Date
11-05-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$845,522,000.00
N/A
Revenue This Year
$21.54
N/A
Revenue Next Year
$15.73
N/A
P/E Ratio
N/A
N/A
Revenue Growth
19.86
N/A
52 Week Low
$60.50
$21.34
52 Week High
$116.83
$58.40

Technical Indicators

Market Signals
Indicator
WK
AKRO
Relative Strength Index (RSI) 57.63 66.54
Support Level $89.69 $54.22
Resistance Level $93.44 $54.70
Average True Range (ATR) 2.35 0.14
MACD -0.01 -0.11
Stochastic Oscillator 77.29 64.18

Price Performance

Historical Comparison
WK
AKRO

About WK Workiva Inc.

Workiva Inc is a cloud-native platform that simplifies the complexities of reporting and compliance. Workiva platform empowers customers by connecting and transforming data from hundreds of enterprise resource planning (ERP), human capital management (HCM), and customer relationship management (CRM) systems, as well as other third-party cloud and on-premise applications. Customers use the platform to create, review and publish data-linked documents and reports with greater control, consistency, accuracy, and productivity and it is also used for SEC Filings. Company's Geographical region consist of USA, Netherland, UK, and Others. Majority of revenue is from USA.

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Share on Social Networks: